Myocardial Involvement in Chagas Disease and Insulin Resistance: A Non-Metabolic Model of Cardiomyopathy.


Journal

Global heart
ISSN: 2211-8179
Titre abrégé: Glob Heart
Pays: England
ID NLM: 101584391

Informations de publication

Date de publication:
24 04 2020
Historique:
entrez: 4 6 2020
pubmed: 4 6 2020
medline: 14 4 2021
Statut: epublish

Résumé

Heart failure (HF) and type 2 Diabetes Mellitus (T2DM) represent two chronic interrelated conditions accounting for significant morbidity and mortality worldwide. Insulin resistance (IR) has been identified as a risk factor for HF; however, the risk of IR that HF confers has not been well elucidated. The present study aims to analyze the association between myocardial involvement in Chronic Chagas Cardiomyopathy (CCM) and IR, taking advantage of this non-metabolic model of the disease. Cross-sectional study performed during the period 2015-2016. Adults with a serological diagnosis of Chagas disease were included, being divided into two groups: CCM and non-CCM. IR was determined by HOMA-IR index. Bivariate analysis and multivariate logistic regression were performed to determine the association between IR as an outcome and CCM as primary exposure. 200 patients were included in the study, with a mean age of 54.7 years and a female predominance (53.5%). Seventy-four (37.0%) patients were found to have IR, with a median HOMA-IR index of 3.9 (Q1 = 3.1; Q3 = 5.1). Multiple metabolic variables were significantly associated with IR. In a model analyzing only individuals with an altered HWI, an evident association between CCM and IR was observed (OR 4.08; 95% CI 1.55-10.73, p = 0.004). CCM was significantly associated with IR in patients with an altered HWI. The presence of this association in a non-metabolic model of HF (in which the myocardial involvement is expected to be mediated mostly by the parasitic infection) may support the evidence of a direct unidirectional correlation between this last and IR.

Sections du résumé

Background
Heart failure (HF) and type 2 Diabetes Mellitus (T2DM) represent two chronic interrelated conditions accounting for significant morbidity and mortality worldwide. Insulin resistance (IR) has been identified as a risk factor for HF; however, the risk of IR that HF confers has not been well elucidated. The present study aims to analyze the association between myocardial involvement in Chronic Chagas Cardiomyopathy (CCM) and IR, taking advantage of this non-metabolic model of the disease.
Methods
Cross-sectional study performed during the period 2015-2016. Adults with a serological diagnosis of Chagas disease were included, being divided into two groups: CCM and non-CCM. IR was determined by HOMA-IR index. Bivariate analysis and multivariate logistic regression were performed to determine the association between IR as an outcome and CCM as primary exposure.
Results
200 patients were included in the study, with a mean age of 54.7 years and a female predominance (53.5%). Seventy-four (37.0%) patients were found to have IR, with a median HOMA-IR index of 3.9 (Q1 = 3.1; Q3 = 5.1). Multiple metabolic variables were significantly associated with IR. In a model analyzing only individuals with an altered HWI, an evident association between CCM and IR was observed (OR 4.08; 95% CI 1.55-10.73, p = 0.004).
Conclusion
CCM was significantly associated with IR in patients with an altered HWI. The presence of this association in a non-metabolic model of HF (in which the myocardial involvement is expected to be mediated mostly by the parasitic infection) may support the evidence of a direct unidirectional correlation between this last and IR.

Identifiants

pubmed: 32489809
doi: 10.5334/gh.793
pmc: PMC7218788
doi:

Substances chimiques

Blood Glucose 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

36

Informations de copyright

Copyright: © 2020 The Author(s).

Déclaration de conflit d'intérêts

The authors have no competing interests to declare.

Références

Am J Cardiol. 1974 Jul;34(1):29-34
pubmed: 4835750
PLoS One. 2015 Jul 06;10(7):e0131447
pubmed: 26147101
Rev Soc Bras Med Trop. 1999 Sep-Oct;32(5):489-96
pubmed: 10881081
Heart Fail Clin. 2012 Oct;8(4):609-17
pubmed: 22999243
Am Heart J. 2011 Nov;162(5):938-948.e2
pubmed: 22093212
Nat Rev Cardiol. 2012 Oct;9(10):576-89
pubmed: 22847166
Hosp Pract (1995). 2014 Aug;42(3):116-22
pubmed: 25255413
Metabolism. 1991 Sep;40(9):972-7
pubmed: 1895963
Circulation. 2003 Mar 11;107(9):1291-6
pubmed: 12628950
Diabetes Care. 2005 Mar;28(3):612-6
pubmed: 15735197
Circulation. 2018 Sep 18;138(12):e169-e209
pubmed: 30354432
Diabetes Care. 2004 Jun;27(6):1487-95
pubmed: 15161807
Eur J Heart Fail. 2010 Dec;12(12):1333-8
pubmed: 20864482
Circulation. 2005 Jul 5;112(1):48-53
pubmed: 15983242
Wei Sheng Yan Jiu. 2012 Mar;41(2):308-10
pubmed: 22611946
Diabetologia. 2011 Mar;54(3):523-6
pubmed: 21107522
Heart Surg Forum. 2014 Apr;17(2):E98-102
pubmed: 24808450
J Am Coll Cardiol. 2009 Mar 3;53(9):747-53
pubmed: 19245964
Eur Heart J. 2006 Nov;27(22):2725-36
pubmed: 17000631
Parasitol Res. 2017 Mar;116(3):827-838
pubmed: 28013375
Eur J Heart Fail. 2011 Feb;13(2):195-9
pubmed: 21098576
ASAIO J. 2014 May-Jun;60(3):290-3
pubmed: 24614357
Can J Physiol Pharmacol. 2019 Feb;97(2):140-145
pubmed: 30557036
Adv Parasitol. 2011;76:235-50
pubmed: 21884894
Heart Fail Rev. 2014 Sep;19(5):595-602
pubmed: 24174218
Am Heart J. 2005 Feb;149(2):209-16
pubmed: 15846257
Am J Epidemiol. 2009 Apr 1;169(7):837-47
pubmed: 19224980
Circ Heart Fail. 2017 Nov;10(11):
pubmed: 29141857
Infect Dis Clin North Am. 2019 Mar;33(1):119-134
pubmed: 30712757
Oncotarget. 2016 Mar 22;7(12):13400-15
pubmed: 26921251
Diabetes Metab. 1997 Jun;23(3):213-8
pubmed: 9233998
Cardiology. 2014;129(2):84-92
pubmed: 25138610
Ann Epidemiol. 2011 May;21(5):358-66
pubmed: 21458729
Eur Heart J. 2008 May;29(10):1224-40
pubmed: 18424786

Auteurs

Luis E Echeverría (LE)

Public Health and Epidemiological Studies Group, Cardiovascular Foundation of Colombia, Floridablanca, CO.
Heart Failure and Heart Transplant Clinic, Fundación Cardiovascular de Colombia, Floridablanca, Santander, CO.

Lyda Z Rojas (LZ)

Public Health and Epidemiological Studies Group, Cardiovascular Foundation of Colombia, Floridablanca, CO.
Research Group and Development of Nursing Knowledge (GIDCEN-FCV), Research Institute, Cardiovascular Foundation of Colombia, Floridablanca, Santander, CO.

Luis A López (LA)

Research Group and Development of Nursing Knowledge (GIDCEN-FCV), Research Institute, Cardiovascular Foundation of Colombia, Floridablanca, Santander, CO.

Oscar L Rueda-Ochoa (OL)

Electrocardiography Research Group, Universidad Industrial de Santander, Bucaramanga, CO.

Sergio Alejandro Gómez-Ochoa (SA)

Public Health and Epidemiological Studies Group, Cardiovascular Foundation of Colombia, Floridablanca, CO.

Carlos A Morillo (CA)

Department of Cardiac Sciences, Cumming School of Medicine, University of Calgary, Alberta, CA.
Department of Medicine, Cardiology Division, McMaster University, PHRI-HHSC, Hamilton, Ontario, CA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH